Amylyx Pharmaceuticals Inc (AMLX) AI Stock Analysis

• Market Cap: $889.89M
• Dividend Yield: N/A
• Average Volume (3M): 1.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: -100.08%
• EPS Growth: -2.45%
• Country: US
• Employees: 123
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.46
• Shares Outstanding: 89,167,435
• 10 Day Avg. Volume: 1,778,331
• 30 Day Avg. Volume: 1,238,384
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: -1.59K
• Enterprise Value/Gross Profit: -291.77
• Enterprise Value/Ebitda: -2.03
• 1Y Price Target: $13.00
• Price Target Upside: 30.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 57 Neutral
• Price Target: $9.50 ▼(-4.52% Downside)

Amylyx Pharmaceuticals' overall stock score is primarily impacted by its financial performance challenges, including declining revenues and operational losses. While technical analysis shows positive momentum, the company's valuation is weak due to a negative P/E ratio and lack of dividends. The recent halt of the ORION program further adds to the uncertainty, despite some positive developments in other clinical trials.

Positive Factors

Clinical Trials

The company presented positive 48-week long-term data from the Phase 2 HELIOS trial, showing sustained improvement in key health metrics.

Market Opportunity

KOL discussions at ENDO, coupled with ASMBS survey data and Lee et al., suggest the medically important PBH population could exceed the commonly cited 167,000 patients, highlighting a significant market opportunity.

Pricing Potential

Avexitide’s orphan and breakthrough therapy designations suggest it can command premium pricing, estimated at $144,000 per patient annually.

Negative Factors

Awareness Issues

There might be work needed in terms of awareness, especially among primary care physicians, with respect to early diagnosis and establishment of an official PBH code.

Diagnosis Challenges

Absence of ICD-10 coding and severe underdiagnosis undermines the true prevalence of the disease.

Amylyx Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Amylyx Pharmaceuticals Inc generates revenue primarily through the commercialization of its therapeutic products. The company's revenue model is centered around the sale of AMX0035, which has been developed for the treatment of neurodegenerative diseases like ALS. Revenue streams include product sales in approved markets and potential partnerships or collaborations with other pharmaceutical companies for distribution and further development. Regulatory approvals and successful market penetration are significant factors contributing to its earnings. However, as a company in the biotechnology industry, research and development activities also play a crucial role in advancing its pipeline and supporting future revenue growth.

Amylyx Pharmaceuticals Inc Financial Statement Overview

Summary

Amylyx Pharmaceuticals faces significant financial challenges, with declining revenues and substantial operational losses reflected in negative profit margins. The balance sheet shows a relatively low level of debt and strong equity ratio, although historical negative equity points to potential financial instability. Cash flow analysis reveals persistent cash generation issues, which could impact future operational sustainability.

Income Statement

The company's revenue showed a significant decrease from 2023 to 2024, indicating a revenue growth rate of -77.05%. Despite having a gross profit margin of 51.76% in 2024, the net profit margin was highly negative at -345.20%, reflecting substantial operational losses. The EBIT and EBITDA margins were also negative, highlighting ongoing profitability challenges.

Balance Sheet

Amylyx Pharmaceuticals maintains a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt. However, the company has a strong equity ratio of 85.10%, indicating that a majority of the assets are financed by shareholders' equity. Despite this, the company has consistently reported negative equity in previous years, pointing to financial instability risks.

Cash Flow

The company experienced a decline in free cash flow from 2023 to 2024, with a negative growth rate of -1671.46%. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. This indicates ongoing cash flow challenges, as the company is not generating sufficient cash from operations to cover its expenses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-249.00K	87.37M	380.79M	22.23M	285.00K	650.00K
Gross Profit	-1.36M	-37.26M	355.35M	19.24M	233.00K	-23.94M
EBITDA	-194.88M	-290.98M	39.89M	-200.85M	-82.64M	-39.00M
Net Income	-187.60M	-301.74M	49.27M	-198.38M	-87.88M	-44.84M
Balance Sheet
Total Assets	194.60M	193.63M	517.45M	391.45M	105.61M	14.10M
Cash, Cash Equivalents and Short-Term Investments	180.83M	176.50M	371.36M	346.94M	96.12M	12.88M
Total Debt	5.96M	1.98M	4.24M	6.28M	0.00	1.43M
Total Liabilities	26.72M	28.87M	84.02M	50.85M	256.78M	80.83M
Stockholders Equity	167.88M	164.76M	433.43M	340.61M	-151.17M	-66.72M
Cash Flow
Free Cash Flow	-165.68M	-167.80M	10.68M	-182.40M	-75.15M	-36.85M
Operating Cash Flow	-165.65M	-167.65M	11.92M	-179.87M	-74.80M	-36.70M
Investing Cash Flow	83.13M	75.65M	92.05M	-238.99M	-46.41M	-151.00K
Financing Cash Flow	65.82M	348.00K	3.54M	431.79M	158.51M	46.82M

Amylyx Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 9.95 is above the 20-day moving average (MA) of 8.67, above the 50-day MA of 8.02, and above the 200-day MA of 5.21, indicating a bullish trend. The MACD of 0.56 indicates Negative momentum. The RSI at 67.64 is Neutral, neither overbought nor oversold. The STOCH value of 94.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.

Amylyx Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETON	66 Neutral	$460.99M	―	-22.06%	―	85.40%	40.95%
ZBIO	58 Neutral	$715.03M	―	-88.40%	―	―	―
AMLX	57 Neutral	$889.89M	―	-87.42%	―	-100.08%	-2.45%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
BNTC	47 Neutral	$361.60M	―	-48.57%	―	-100.00%	83.98%
CKPT	45 Neutral		―		―	-60.19%	56.60%
ALLO	42 Neutral	$246.29M	―	-55.12%	―	-100.00%	30.91%

Amylyx Pharmaceuticals Inc Corporate Events

Amylyx Pharmaceuticals Halts ORION Program for AMX0035

On August 27, 2025, Amylyx Pharmaceuticals announced the discontinuation of its ORION program for AMX0035 in adults with progressive supranuclear palsy, as the drug showed no significant differences compared to placebo in primary or secondary outcomes at Week 24. Consequently, the company will halt the Phase 2b trial and open-label extension, and will not proceed with the Phase 3 portion, although safety data remained consistent with previous studies.

Amylyx Pharmaceuticals Inc Holds Annual Stockholder Meeting

On June 5, 2025, Amylyx Pharmaceuticals Inc. held its Annual Meeting of Stockholders where three key proposals were voted on. The stockholders elected Karen Firestone, Justin Klee, and Bernhardt Zeiher, M.D. as Class I directors for a three-year term. They also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved, on an advisory basis, the compensation of the Company’s named executive officers.